|
|
|
| Webinar: Flexible Therapeutic Development: Balancing Speed, Cost, and Process | Behind every molecule is a unique development strategy. In this webinar, KBI Biopharma showcases its flexible microbial protein platforms designed to accelerate first-in-human programs with speed, cost-efficiency, and process robustness. Explore considerations in cell line development, fermentation, and purification, and learn how platform-based approaches and robotic workflows align milestones from proof-of-concept through toxicology material generation with no license fee to evaluate. Click here to learn more. |
|
|
|
| Optimization Of A Glycosylation Analytical Method | White Paper | By Eliza Yeung, Ph.D. and Philip Ramsey, Ph.D., Cytovance Biologics | The predictive models created using “self-validating ensemble modeling (SVEM)” on the definitive screening design data reliably predicted the behavior of the chosen responses. |
|
|
|
| Getting To The Heart Of CDMO Tech Transfer Excellence | Article | Bora Pharmaceuticals | Discover five key factors that drive a seamless and efficient technology transfer, highlighting how a culture of technical expertise, customer focus, and operational flexibility is crucial to success. |
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | GeoVax CEO David Dodd sings the praises and is grateful for the program-enabling relationships he has in Europe. At the same time, he harbors lingering disappointment. From the outset of its formation, the biotech has desired to work with U.S.-based CDMOs. But he says he will not give up. “One way or the other,” Dodd says, “GeoVax will have U.S.-based manufacturing.” | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| Developing New Medicines Through Artificial Intelligence | Article | By Tony Reina, Resilience, LLC. | Embrace the future of drug development by leveraging AI and innovative protein synthesis technologies to accelerate the creation of effective therapies and transform patient outcomes. |
|
|
|
|
| End-To-End Biologics Support | Case Study | Curia | What does it take to move a molecule from concept to clinic? It’s often more steps – and more time – than biotechs think. |
|
|
|
|
|
|
|
|
| Join us for two Outsourced Pharma Capabilities Update sessions featuring leading CDMOs sharing their facilities, timelines, and available capacity for development and manufacturing. The April 21st session focuses on small molecule drug product capabilities, while April 22nd highlights fill-finish technologies including sterile filling, lyophilization, and advanced packaging. Expect short digital presentations to help biopharma companies identify partners that can meet their manufacturing needs. Click to learn more. |
|
|
|
Expertise At Every Step | August Bioservices | We specialize in sterile injectable development and manufacturing, offering expert teams, modern facilities, and broad capabilities through collaborative partnerships. |
|
|
USP <382> Functional Suitability & CCI Testing | Pace Life Sciences | USP <382> testing assesses packaging integrity, safety, and performance using deterministic CCIT and functional evaluations to support validation and regulatory submissions. |
|
|
A Leading Drug Delivery CDMO | Kindeva | A look at integrated drug‑delivery expertise, scalable development paths, and advanced manufacturing that speed programs from formulation to global launch while reducing risk and improving efficiency. |
|
|
|
Speeding IND Timelines | Thermo Fisher Scientific | You can confidently achieve critical milestones — such as submitting your IND application — or secure additional funding, backed by the robust data, quality, and reliable supply your program demands. |
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
